Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
(NASDAQ:VXRT), SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), to initiate dosing in […]